NUVATION BIO NUVB 深 沪
已收盘 07-02 16:00:00 美东时间
5.70
+0.280
+5.17%
华盛通- 最 高5.72
- 今 开5.42
- 成交量 633.20万股
- 最 低 5.39
- 昨 收 5.42
- 总市值 19.85亿
- 52周最高 9.75
- 市盈率 静 --
- 换手率 1.82%
- 52周最低 2.06
- 委 比 -64.59%
- 总股本 3.48亿
- 历史最高 15.23
- 量 比 0.34
- 振 幅 6.09%
- 历史最低 0.95
- 每 手 1
- 风险率 1.82%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多H.B. Fuller, Trip.com, Hertz Global And Other Big Stocks Moving Lower In Thursday Pre-Market Session
U.S. stock futures were higher this morning, with the Nasdaq 100 futures gaining more than 2% on Thursday. Shares of H.B. Fuller Company (NYSE:FUL) fell sharply in pre-market trading following second-quarter results. H.B. Fuller posted upbeat earnings for the second quarter and raised its FY2026 ear...
06-25 20:08
Nuvation Bio Intends To Offer $200M Aggregate Principal Amount Of Convertible Senior Notes Due In 2032
Nuvation Bio Inc. ("Nuvation Bio") (NYSE:NUVB), a global oncology company focused on tackling some of the toughest challenges in cancer treatment, today announced its intent to offer, subject to market conditions and other factors, $200.0 million aggregate principal amount of Convertible Senior Note...
06-25 19:13
Shares of pharmaceutical companies are trading higher as investors rotate out of chips stocks and move into non-tech industries.
Shares of pharmaceutical companies are trading higher as investors rotate out o...
06-05 02:13
Nuvation Bio To Showcase New Outcomes Data From Its Pivotal TRUST-II Trial Of IBTROZI In Participants With Advanced ROS1-Positive Non-Small Cell Lung Cancer
Nuvation Bio Inc. (NYSE:NUVB), a global oncology company focused on tackling some of the toughest challenges in cancer treatment, today announced new patient-reported outcomes data from the pivotal TRUST-II study of
05-27 20:06
美股大行评级 | Stifel上调Lumentum控股目标价从800美元升至1100美元；Pinterest、先进能源工业、安森美半导体、莱迪思半导体、V2X等获多家大行上调目标价
今日重点评级关注：Piper Sandler：维持Aclaris Therapeutics"超配"评级，目标价从7美元升至11美元；Evercore ISI集团：维持BioMarin Pharmaceutical"跑赢大市"评级，目标价从110美元升至120美元
05-06 11:29
HC Wainwright & Co. Reiterates Buy on Nuvation Bio, Maintains $17 Price Target
HC Wainwright & Co. analyst Robert Burns reiterates Nuvation Bio (NYSE:NUVB) with a Buy and maintains $17 price target.
05-05 18:26
财报速睇 | NUVATION BIO 2026财年Q1营收0.83亿美元，同比增长2598.7%；归母净利润0.05亿美元，扭亏为盈
华盛资讯5月5日讯，NUVATION BIO公布2026财年Q1业绩，公司Q1营收0.83亿美元，同比增长2598.7%，归母净利润0.05亿美元，扭亏为盈。
05-05 12:35
财报速睇 | NUVATION BIO 2026财年Q1营收0.83亿美元，同比增长2666.7%；归母净利润0.05亿美元，扭亏为盈
华盛资讯5月5日讯，NUVATION BIO公布2026财年Q1业绩，公司Q1营收0.83亿美元，同比增长2666.7%，归母净利润0.05亿美元，扭亏为盈。
05-05 04:46
Nuvation Bio Q1 EPS $0.01, Inline, Sales $83.228M Beat $62.259M Estimate.
Nuvation Bio (NYSE:NUVB) reported quarterly earnings of $0.01 per share which met the analyst consensus estimate. This is a 106.25 percent increase over losses of $(0.16) per share from the same period last year. The
05-05 04:13
Earnings Scheduled For May 4, 2026
Companies Reporting Before The Bell • Pulse Biosciences (NASDAQ:PLSE) is likely...
05-04 19:11
